Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Russell 2000 ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while iShares Russell 2000 ETF trades at $293.41. The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | IWM | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $300.45 |
52-Week Low | $10.24 | $214.95 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IWM (iShares Russell 2000 ETF) trades at $298.90, up 0.46% with a bullish technical signal supported by moving averages. The ETF holds nearly 2,000 small-cap stocks and has gained 22.1% year-to-date, outperforming major indices. Recent news highlights small-cap strength amid shifting rate expectations, though key financial ratios remain undisclosed in current data.
Outlook remains positive given small-cap momentum and potential rate cuts, but risks include higher volatility and economic sensitivity. The ETF's diversification offers growth exposure, yet investors should weigh valuation concerns and market concentration against historical underperformance versus broad market indices over longer periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
